Fradet Y - Search Results

1

Neoadjuvant hormonal therapy: the Canadian experience.

Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Bélanger A, Candas B. Labrie F, et al. Among authors: fradet y. Urology. 1997 Mar;49(3A Suppl):56-64. doi: 10.1016/s0090-4295(97)00170-2. Urology. 1997. PMID: 9123738 Clinical Trial.

2

Total androgen ablation: Canadian experience.

Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD. Béland G, et al. Among authors: fradet y. Urol Clin North Am. 1991 Feb;18(1):75-82. Urol Clin North Am. 1991. PMID: 1992574 Clinical Trial.

3

Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy.

Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Têtu B, Fradet Y, Candas B. Labrie F, et al. Among authors: fradet y. Cancer Surv. 1995;23:149-56. Cancer Surv. 1995. PMID: 7621455 Clinical Trial.

4

Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.

Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, et al. Labrie F, et al. Among authors: fradet y. Clin Invest Med. 1993 Dec;16(6):499-509. Clin Invest Med. 1993. PMID: 8013155 Clinical Trial.

5

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.

Vailancourt L, Ttu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F. Vailancourt L, et al. Among authors: fradet y. Am J Surg Pathol. 1996 Jan;20(1):86-93. doi: 10.1097/00000478-199601000-00010. Am J Surg Pathol. 1996. PMID: 8540613 Clinical Trial.

6

Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.

Van der Kwast TH, Têtu B, Fradet Y, Dupont A, Gomez J, Cusan L, Diamond P, Labrie F. Van der Kwast TH, et al. Among authors: fradet y. Prostate. 1996 Apr;28(4):227-31. doi: 10.1002/(SICI)1097-0045(199604)28:4<227::AID-PROS3>3.0.CO;2-A. Prostate. 1996. PMID: 8602398

7

Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer.

Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P. Tetu B, et al. Among authors: fradet y. J Urol. 1996 May;155(5):1784-8. J Urol. 1996. PMID: 8627884

8

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.

Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ, Laplante S. Goldenberg SL, et al. Among authors: fradet y. J Urol. 1996 Sep;156(3):873-7. J Urol. 1996. PMID: 8709351 Clinical Trial.

9

Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer.

Têtu B, Allard P, Fradet Y, Roberge N, Bernard P. Têtu B, et al. Among authors: fradet y. Hum Pathol. 1996 Sep;27(9):922-6. doi: 10.1016/s0046-8177(96)90219-1. Hum Pathol. 1996. PMID: 8816887

10

The role of neoadjuvant androgen deprivation prior to radical prostatectomy.

Fradet Y. Fradet Y. Urol Clin North Am. 1996 Nov;23(4):575-85. doi: 10.1016/s0094-0143(05)70337-2. Urol Clin North Am. 1996. PMID: 8948412 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

345 results

Search Page